BeiGene | Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

Beigene Study ID

BGB-A317-310

ClinicalTrials.gov ID

NCT03967977

China Drug Trials ID

CTR20190543

Sex: All

Age: 18 Years / 75 Years

No Study Documents

Locations

Sex: All

Age: 18 Years / 75 Years

No Study Documents